

## AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application.

### Claims:

134. (Currently amended) An oligopeptide having the amino acid sequence:  
Arg-nL-nL-nL-Arg-nL-nL-nL-Gly-Tyr (SEQ ID NO:13).
235. (Currently amended) The oligopeptide according to Claim 134, wherein one or more of the amino acids of said oligopeptide are D isomers.
336. (Currently amended) The oligopeptide according to Claim 235, wherein all the amino acids of said oligopeptide, other than glycine, are D isomers.
437. (Currently amended) The oligopeptide according to any one of Claims 134 to 336, wherein the terminal carboxyl group of said oligopeptide is amidated.
538. (Currently amended) The oligopeptide according to Claim 437, wherein said terminal carboxyl group is the acetate salt of an amide.
639. (Currently amended) An oligopeptide having the structural formula:  
H-(D)Arg-(D)nL-(D)nL-(D)nL-(D)Arg-(D)nL-(D)nL-(D)nL-Gly-(D)Tyr-NH<sub>2</sub>.
740. (Currently amended) A pharmaceutical composition comprising an oligopeptide according to any one of Claims 134 to 639 and a pharmaceutically acceptable medium.
841. (Currently amended) The pharmaceutical composition according to ~~of one~~ Claim 740, wherein said pharmaceutically acceptable medium comprises an excipient.
942. (Currently amended) The pharmaceutical composition according to Claim 8 ~~of claim~~ 41, wherein said excipient comprises mannitol.